Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Clene Inc (CLNN)

Clene Inc (CLNN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 43,655
  • Shares Outstanding, K 128,434
  • Annual Sales, $ 650 K
  • Annual Income, $ -49,500 K
  • 60-Month Beta 0.47
  • Price/Sales 68.93
  • Price/Cash Flow N/A
  • Price/Book 10.57
Trade CLNN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.29
  • Most Recent Earnings $-0.09 on 05/08/24
  • Next Earnings Date 05/10/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 381.81% ( +10.20%)
  • Historical Volatility 80.07%
  • IV Percentile 81%
  • IV Rank 32.01%
  • IV High 1,068.19% on 04/24/24
  • IV Low 58.66% on 01/17/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 118
  • Volume Avg (30-Day) 42
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 10,270
  • Open Int (30-Day) 10,136

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.08
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3128 +8.66%
on 05/28/24
0.4397 -22.70%
on 05/03/24
unch (unch)
since 04/26/24
3-Month
0.3040 +11.81%
on 04/16/24
0.5200 -34.63%
on 03/08/24
-0.0941 (-21.68%)
since 02/28/24
52-Week
0.2500 +35.96%
on 12/27/23
1.0900 -68.82%
on 06/15/23
-0.6032 (-63.96%)
since 05/26/23

Most Recent Stories

More News
Clene (NASDAQ: CLNN) Participates in Three Investor Conferences During May 2024

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic...

CLNN : 0.3399 (-3.16%)
Clene (NASDAQ: CLNN) Looking to Transform Healthcare for Individuals with Neurodegenerative Diseases

Clene (NASDAQ: CLNN) has innovated CNM-Au8(R), an oral nanotherapeutic designed to revitalize the brain’s mitochondrial function, which is a significant advancement for the treatment of neurodegenerative...

CLNN : 0.3399 (-3.16%)
Clene (NASDAQ: CLNN) Announces Operational Highlights as part of Q1 2024 Financial Results

Clene (NASDAQ: CLNN), a late-stage clinical biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple...

CLNN : 0.3399 (-3.16%)
Clene (NASDAQ: CLNN) Announces Participation Schedule for May Conferences

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial...

CLNN : 0.3399 (-3.16%)
Clene (NASDAQ: CLNN) Releases Q1 2024 Financial Numbers, Operation Highlights

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., are reporting on first-quarter 2024 financial results and operating highlights for its CNM-Au8 clinical program for amyotrophic...

CLNN : 0.3399 (-3.16%)
Clene (NASDAQ: CLNN) Presents Findings on Phase 2 VISIONARY-MS LTE at American Academy of Neurology Annual Meeting

Clene (NASDAQ: CLNN), along with its subsidies, “Clene”, and its wholly owned subsidiary Clene Nanomedicine, Inc., a pioneering clinical-stage biopharmaceutical firm dedicated to enhancing mitochondrial...

CLNN : 0.3399 (-3.16%)
Clene (NASDAQ: CLNN) Continues Development of CNM Au8(R) for Neurodegenerative Diseases

In recognition of April as Parkinson’s Disease Awareness Month, IBN is highlighting Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and...

CLNN : 0.3399 (-3.16%)
Clene (NASDAQ: CLNN) Announces Study Results for CNM-Au8 as MS Treatment Presented at AAN Conference

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., announced that results from a phase 2 Visionary-MS long-term extension (“LTE”)...

CLNN : 0.3399 (-3.16%)
Clene (NASDAQ: CLNN) Looking to Advance Discussions for Accelerated Approval, New NDA for CNM-Au8(R)

Clene (NASDAQ: CLNN), alongside its wholly owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function...

CLNN : 0.3399 (-3.16%)
Clene (NASDAQ: CLNN) has Emerged as a Leader in the Neurodegenerative Field Utilizing a Novel Nanotherapeutic Drug

In a significant advancement for the treatment of neurodegenerative diseases, Clene (NASDAQ: CLNN) has innovated CNM-Au8, an oral nanotherapeutic designed to revitalize the brain’s mitochondrial function....

CLNN : 0.3399 (-3.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Clene Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of unique therapeutics for neurodegenerative diseases. Clene Nanomedicine Inc., formerly known as Tottenham Acquisition I Limited, is based in SALT LAKE CITY.

See More

Key Turning Points

3rd Resistance Point 0.4559
2nd Resistance Point 0.4218
1st Resistance Point 0.3809
Last Price 0.3399
1st Support Level 0.3059
2nd Support Level 0.2718
3rd Support Level 0.2309

See More

52-Week High 1.0900
Fibonacci 61.8% 0.7691
Fibonacci 50% 0.6700
Fibonacci 38.2% 0.5709
Last Price 0.3399
52-Week Low 0.2500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar